JonesResearch initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $33 price target Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia, the analyst tells investors in a research note. The firm says the company is “gearing up for a transformative year” with two major datasets in the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics
- Aardvark Therapeutics initiated with a Buy at Stifel
- Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment
- Aardvark Therapeutics: Undervalued Opportunity in Obesity Treatment Market with Promising Pipeline and Upcoming Catalysts
- Aardvark Therapeutics reports inducement grants under Nasdaq listing rule